19.03.2013 - British-Swedish drugmaker AstraZeneca has announced to restructure its operations, axing 1,600 jobs and relocating 2,500 employees.
It is the third time in three years that the British-Swedish pharma company is going to restructure its R&D. The company said it will concentrate its R&D in the UK. A third of the US-$1.4bn restructuring cost will be invested in a new R&D complex in the UK, unifying the company’s small molecule and biologics research under one roof in Cambridge. About 1,600 researchers will be relocated from Alderley Park to the new site. By 2016, AstraZeneca will remove its current headquarters from London to the new Cambridge site. Steve Bates, chief of the British Industry Association applauded the decision; "I am pleased that AstraZeneca has seen the value of the UK as a global hub for bioscience and we welcome its £330 million investment in consolidating its R&D activities and its global headquarters in Cambridge.“
In the US, the company will move its Global Medicines Development Group from Wilmington to Gaithersburg, the headquarters of its biologics subsidiary MedImmune. The company announced it will axe 650 jobs in the US. Small molecule research in Sweden will remain. With the measures the drug giant aims at improving its R&D productivity, leaving three global R&D centres.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
The Development Microlute™ from Porvair Sciences is a Solid Phase Extraction (SPE) microplate which provides a wide assortment of phase chemistries and sorbent loadings in a single plate making it ideally suited for method development. more